New hope for BRCA breast cancer: could cisplatin beat standard chemo?

NCT ID NCT01670500

Completed Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether cisplatin, a platinum-based chemo, works better than the standard doxorubicin/cyclophosphamide (AC) combo in women with newly diagnosed breast cancer who carry a BRCA mutation. 118 participants received either cisplatin or AC before surgery. The main goal was to see which treatment led to a higher rate of complete tumor disappearance (pathologic complete response).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cisplatin, Doxorubicin, Cyclophosphamide
What this could lead to: If cisplatin works better, it could offer a more effective chemotherapy option for women with BRCA-related breast cancer.
What could go wrong: This is a small Phase 2 trial, so results may not apply to all patients. Cisplatin also has side effects like kidney damage and nerve issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27708, United States
Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016-2698, United States
Smilow Cancer Hospital Care Center at Derby

Derby, Connecticut, 06418, United States
Smilow Cancer Hospital Care Center at Guilford

Guilford, Connecticut, 06437, United States
St. Francis Hospital and Medical Center

Hartford, Connecticut, 06105, United States
University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
Women and Infants Hospital

Providence, Rhode Island, 02905, United States
Yale School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.